Near-infrared Spectroscopy in Cerebral Oxygenation Monitoring in Full Term Neonates
Use of Near-infrared Spectroscopy in Cerebral Oxygenation Monitoring in Full Term Neonates During Transition After Birth
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Alexandria, Egypt, 21131
- Neonatal Intensive Care Unit (NICU) of Alexandria University Maternity Hospital.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Gestational age ≥38 weeks, without any medical support and normal pregnancy development.
Exclusion Criteria:
- Newborns with gestational age <38 weeks.
- Newborns with intrauterine growth restriction.
- Evidence of perinatal depression (hypoxic ischemic encephalopathy).
- The need for respiratory support or oxygen therapy in the first 10 minutes of life.
- Suspected or known brain malformations or congenital cyanotic heart disease.
- Birth complications (e.g. vacuum extraction or forceps application).
- Newborn delivered through cesarean section with previous attempts of normal vaginal delivery.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Neonates delivered by normal vaginal delivery
|
Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion.
Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
|
|
Neonates delivered by elective cesarean section.
|
Near-infrared spectroscopy (NIRS) offers the non-invasive continuous monitoring of cerebral oxygenation and perfusion.
Cerebral regional oxygen (crSO2) measured via NIRS represents a mixed tissue saturation value, thus enabling information on the balance of cerebral oxygen delivery and oxygen consumption.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral regional oxygen saturation monitoring (crSO2)
Time Frame: the first 10 minutes of life
|
Measurements was done by using Near infrared spectroscopy (INVOSTM 5100C Cerebral/ Somatic Oximeter Monitor; Covidien) by placing a neonatal brain sensor on the left frontoparietal area of the newborn's head.
|
the first 10 minutes of life
|
|
Peripheral oxygen saturation monitoring (SpO2)
Time Frame: the first 10 minutes of life
|
Oxygen saturation was measured using pulse oximeter (Masimo or Nellcor) by applying a preductal pulseoximetry sensor to the right wrist.
|
the first 10 minutes of life
|
|
Blood gas analysis
Time Frame: up to 10 minutes of life
|
It was performed from umbilical cord blood.
All newborns will be clinically observed and evaluated during this period by a neonatologist, and clinical status will be assessed by Apgar score.
The Apgar score is based on a total score of 1 to 10.
The higher the score, the better the baby is doing after birth.
A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health.
|
up to 10 minutes of life
|
|
Fractional tissue oxygen extraction (FTOE)
Time Frame: up to 10 minutes of life
|
After measuring peripheral oxygen saturation (SpO2) and cerebral regional oxygen saturation (crSO2). For evaluation of the balance of oxygen delivery and oxygen consumption, calculation of the fractional tissue oxygen extraction can be done using the following equation: FTOE=(SpO2-crSO2)/SpO2 |
up to 10 minutes of life
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Alaa IA Ibrahim, MBBCh, Faculty of Medicine, Alexandria University, Egypt
- Study Director: Hesham A Ghazal, PhD, Faculty of Medicine, Alexandria University, Egypt
- Study Director: Bahaa S Hammad, Faculty of Medicine, Alexandria University, Egypt
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 0106540
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.